{
    "symbol": "ALC",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-16 12:30:03",
    "content": " Implantable sales were $392 million in the quarter, up 11% year-over-year, primarily due to international market recovery, continued demand for Vivity and sales of Hydrus, which was not part of our portfolio last year. Please proceed with your question. Please proceed with your question. Please proceed with your question. So, again, I think as -- one of the things I mentioned earlier was that as, patient volumes get back to normal and that is the flow of patients through the offices, that\u00e2\u0080\u0099s really what we need to grow share, because in order to grow share, you have got to have a switch or a new patient and it\u00e2\u0080\u0099s exciting, I think, for us to see that patient visits are now kind of roughly back to pre-COVID levels and international, in particular, will do well. Please proceed with your question. I think we see the market as becoming a lot more interesting over time as values come in the line with we thing there out to be and I think you have to think of us is, probably, more taking a moderated approach in that kind of -- typically kind of $50 million to $500 million range and every now and again, maybe we dip into an area or something like that. Please proceed with your question. Please proceed with your question. Please proceed with your question. I kind of imagine it picks up as staffing stabilizes and as kind of the noise around the economy kind of stabilizes and I think those two things together, we will have to see, procedures themselves don\u00e2\u0080\u0099t look like they are way off either internationally or in the U.S. really, really just looks like we are getting a mix shift here right now to a little more traditional lenses and I think that bounces around a little bit for a while before it gets better. Please proceed with your question. Please proceed with your question. Please proceed with your question."
}